💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tenecteplase

CHEMBL2108791 Phase 4 Одобрено Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This clot-busting (thrombolytic) medication is used in emergency treatment of heart attacks (myocardial infarction) to dissolve the blood clot blocking a coronary artery. It is given as a single intravenous injection and works by activating plasminogen to break down fibrin clots. It must be given as quickly as possible after a heart attack begins, and carries a risk of serious bleeding.

Терапевтические области

Cardiovascular Disease Respiratory Disease Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Systemic Lupus Erythematosus Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Atrial Fibrillation

Механизм действия

Activates plasminogen to plasmin, the enzyme that degrades fibrin clots. This restores blood flow through occluded vessels by dissolving pathological thrombi.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Activates plasminogen to plasmin, the enzyme that degrades fibrin clots. This restores blood flow through occluded vessels by dissolving pathological thrombi.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This clot-busting (thrombolytic) medication is used in emergency treatment of heart attacks (myocardial infarction) to dissolve the blood clot blocking a coronary artery. It is given as a single intravenous injection and works by activating plasminogen to break down fibrin clots. It must be given as quickly as possible after a heart attack begins, and carries a risk of serious bleeding.

Activates plasminogen to plasmin, the enzyme that degrades fibrin clots. This restores blood flow through occluded vessels by dissolving pathological thrombi.

Yes, Tenecteplase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108791. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.